FPT-CORPORATION
12.4.2021 12:04:18 CEST | Business Wire | Press release
Vietnam's leading tech firm FPT has set digital transformation revenue from overseas markets to hit $209 million in 2021, a whopping increase of 50% on year. The target was announced at FPT's annual share holders' meeting 2021, hosted virtually on Thursday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005448/en/
Despite the challenges of the COVID-19 pandemic, FPT remains optimistic about its outlook.
In 2021, the company hopes to lead Vietnam's digital transformation with a "data-driven and customer-centric" strategy, its annual report reads. The key drivers would be Cloud, RPA, and Low-code services, which are set to grow by 50%, 150% and 150% in revenue, respectively.
Over the next three years, FPT looks to become a "trusted partner" of businesses, committing itself to deliver excellent digital experiences for management and operation through near real-time data platforms.
To achieve this goal, the company has reinforced its framework for digital transformation, FPT Digital Kaizen, encompassing three pillars: Business, Technology, and People. FPT also developed an ecosystem of 77 digital products and solutions, as well as expanded its global network of development centers to Canada, the Middle East, India, and Costa Rica in 2020.
The optimism is also bolstered by a strong business performance in 2020.
Despite the challenges of COVID-19, FPT posted $1.3 billion in revenue in 2020, up 7.6% on year. We also reported positive growth in all foreign markets, including Japan (+9%), the U.S (+8%), Asia-Pacific (28%) and Europe (1%).
Revenue from digital transformation services increased 31 percent from last year, driven by customers' growing demands for Cloud, Internet of Things, and Low-Code.
“In 2020, FPT has made every effort to turn threats into opportunities and be able to uphold our position as the most valuable technology brand in Vietnam. By continuing taking on the strategy of “customer focus at heart” and having the trait of “Think different – Do different”, FPT indeed has what it takes to accomplish all targets set for 2021", Binh said.
Digital transformation has been FPT's focus since 2019, following decades of leading Southeast Asia in IT services. Earlier this year, the company has set up an arm dedicated to consulting services, FPT Digital . FPT sets to become the world's Top 50 provider of digital transformation services by 2030.
About FPT Corporation
FPT Corporation is a global leading technology and IT services provider headquartered in Vietnam, with nearly US$1.3 billion in revenue and 30,000 employees. As a pioneer in digital transformation, FPT delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Enterprise Mobility, Cloud, AR/VR, Business Applications, Application Services, BPO, and so on. The company has served over 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Automotive, Banking and Finance, Logistics & Transportation, Utilities and more. For more information, please visit www.fpt-software.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005448/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom